{
    "clinical_study": {
        "@rank": "14829", 
        "arm_group": [
            {
                "arm_group_label": "EB-1020 SR1", 
                "arm_group_type": "Active Comparator", 
                "description": "Sustained release formulation"
            }, 
            {
                "arm_group_label": "EB-1020 SR2", 
                "arm_group_type": "Active Comparator", 
                "description": "Sustained Release Formulation"
            }, 
            {
                "arm_group_label": "EB-1020 SR3", 
                "arm_group_type": "Active Comparator", 
                "description": "Sustained Release Formulation"
            }, 
            {
                "arm_group_label": "EB-1020 IR", 
                "arm_group_type": "Active Comparator", 
                "description": "Immediate Release Formulation"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Formulation"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate whether there is a food-effect with oral administration with EB-1020 as well\n      as to obtain information on the safety, and tolerability of EB-1020 in a range of doses."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Normal, Healthy Volunteers", 
        "detailed_description": {
            "textblock": "-  To investigate the safety and tolerance of single doses of EB-1020 immediate release\n           (IR) versus three sustained release (SR) formulations.\n\n        -  To investigate the safety and tolerance of a single oral dose of a SR formulation of\n           EB-1020 in the fed and fasted state.\n\n        -  To investigate the safety, tolerance, and cognitive effects of multiple oral rising\n           doses of a SR formulation of EB-1020.\n\n      Secondary Objectives\n\n        -  To characterize the single dose and steady state pharmacokinetic profiles of EB-1020 SR\n           formulations.\n\n        -  To investigate the effect of food on the pharmacokinetic profile of EB-1020 SR\n           following single oral doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 18-45 years inclusive\n\n          2. Body weight with the normal range for height (body mass index [BMI] between 19-30\n             kg/m2 inclusive)\n\n          3. If female, be of non-child bearing potential (surgically sterile, post-menopausal for\n             12 months or receiving a stable dose of implanted or injectable contraceptive for at\n             least 3 months with last dose of injectable contraceptive within 2 months).\n             Non-surgical menopause history must be confirmed by follicle-stimulating hormone\n             (FSH) and luteinizing hormone (LH) levels as defined by established lab ranges.\n\n          4. Be in general good health without clinically significant medical history\n\n          5. Have clinical laboratory test results that are within the laboratory reference range;\n             or if out of range are not clinically relevant and are acceptable to the Investigator\n             and Sponsor medical representative\n\n          6. Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis Screening test\n\n          7. Able and willing to give written informed consent\n\n        Exclusion Criteria:\n\n          1. Receipt of any investigational agent or drug within 3 months of entry into the study\n\n          2. Use of prescription drugs within 4 weeks prior to first dosing.  Subjects who have\n             used over the counter medication excluding paracetamol, topical over the counter\n             medications and routine vitamins but including megadose (intake of 20 to 600 times\n             the recommended daily dose) vitamin therapy within 7 days of first dosing, unless\n             agreed as non-clinically relevant by the Principal Investigator and Sponsor\n\n          3. A history of, or current evidence for, suicidal ideation, based upon clinical\n             interview and a psychiatric questionnaire\n\n          4. A history of known or suspected seizures, spasms, infantile spasms, febrile\n             convulsions, unexplained significant and recent loss of consciousness or history of\n             significant head trauma with loss of consciousness or a family history (first degree\n             relative) of epilepsy or seizures (fits)\n\n          5. A history of sleep problems in the last 3 months\n\n          6. A history of relevant atopy or drug hypersensitivity\n\n          7. A history (within the last 5 years) or evidence of alcohol or drug abuse.  Subject\n             who consume more than 14 units (female) or 21 (male) units of alcohol a week (unit =\n             1 glass (125 mL) of wine = 1 measure of spirits = \u00bd pint of beer) will also be\n             ineligible\n\n          8. A positive urine test for drugs of abuse or alcohol at Screening or on the day of\n             admittance to the Study Unit\n\n          9. A history of smoking in the last 3 months\n\n         10. Have a significant infection (such as influenza) or known inflammatory process on\n             screening or admission\n\n         11. Have acute gastrointestinal symptoms at the time of screening or admission (e.g.\n             nausea, vomiting, diarrhea, heartburn  )\n\n         12. Have previously received EB-1020\n\n         13. Be vegetarians, vegans or have medical dietary restrictions\n\n         14. Any major surgical procedure within one month of entry into the study\n\n         15. Have difficulties communicating reliably with the Investigator or appear unlikely to\n             co-operate with the requirements of the study in the investigator's judgment.\n\n         16. Any other condition which in the view of the Investigator is likely to interfere with\n             study or put the subject at risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744808", 
            "org_study_id": "EB-1020-102"
        }, 
        "intervention": [
            {
                "arm_group_label": "EB-1020 IR", 
                "description": "Immediate release", 
                "intervention_name": "EB-1020 IR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EB-1020 SR1", 
                "description": "sustained release", 
                "intervention_name": "EB-1020 SR1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EB-1020 SR2", 
                "description": "Sustained release", 
                "intervention_name": "EB-1020 SR2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "EB-1020 SR3", 
                "description": "Sustained release", 
                "intervention_name": "EB-1020 SR3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo formulation", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy", 
            "Normal"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Nucleus Network Ltd."
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Pharmacokinetic parameters", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "Pharmacokinetic parameter", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "Pharmacokinetic parameter", 
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744808"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Effect of food on Cmax", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "source": "Euthymics BioScience, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neurovance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}